Lumen Bioscience Revenue and Competitors
Estimated Revenue & Valuation
- Lumen Bioscience's estimated annual revenue is currently $21.2M per year.
- Lumen Bioscience's estimated revenue per employee is $189,598
- Lumen Bioscience's total funding is $38M.
Employee Data
- Lumen Bioscience has 112 Employees.
- Lumen Bioscience grew their employee count by 13% last year.
Lumen Bioscience's People
| Name | Title | Email/Phone |
|---|---|---|
1 | CEO & Founder | Reveal Email/Phone |
2 | Project Coordinator | Reveal Email/Phone |
3 | Executive Vice President, Production and Development | Reveal Email/Phone |
4 | Scientist | Reveal Email/Phone |
5 | Executive Director at Certara; Vice President, Quantitative Sciences | Reveal Email/Phone |
6 | QA Specialist | Reveal Email/Phone |
7 | VP Finance, Controller | Reveal Email/Phone |
8 | Head of Lab Operations | Reveal Email/Phone |
9 | Principal Scientist | Reveal Email/Phone |
10 | Associate Scientist II | Reveal Email/Phone |
Lumen Bioscience Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $21.2M | 112 | 13% | $38.1M | N/A |
What Is Lumen Bioscience?
Lumen Bioscience develops oral antibody therapeutics.
keywords:N/A
$38M
Total Funding
112
Number of Employees
$21.2M
Revenue (est)
13%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Lumen Bioscience News
Seattle's Lumen Bioscience completed a phase 1 study of its capsules for C. difficile infections, produced with green algae.
Lumen Bioscience Announces Clinical Advancement of LMN-201 for C. difficile Infection. Published: Apr 18, 2022. FDA clearance of investigational new drug...
Lumen Bioscience: Spirulina-based platform enables rapid, low-cost development of oral biologics ... Spirulina has been converted into a...
SEATTLE, Sept. 1, 2021 /PRNewswire/ -- Lumen Bioscience, a clinical-stage biopharmaceutical company developing biologic drugs for highly prevalent diseases, today announced the start of a Phase 1 trial of LMN-Cdiff01, an orally delivered investigational biologic for treatment and prevention of ...
Caitlin Gamble, head of informatics at Lumen Bioscience. (Lumen Photo) Can machine learning help spur the production of algae-based biologics? That’s the question new research from Seattle biotech startup Lumen Bioscience and Google aims to answer. The companies announced a collaboration on We ...
Other Companies in Seattle
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $16.8M | 112 | 1% | $16M |
#2 | $11.2M | 112 | 1% | N/A |
#3 | $7.5M | 112 | 12% | N/A |
#4 | $11.2M | 112 | 5% | N/A |
#5 | $32.5M | 112 | 3% | N/A |